Financials AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:15 2024-12-02 am EST			5-day change	1st Jan Change
10,554.00 ^GBX	-0.55%		+0.76%	-0.43%

Dec. 02	Stockholm Bullets - Alligator Biosciene plunges on rights issue and savings program	FW
Nov. 29	Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	MT

Projected Income Statement: AstraZeneca PLC

income-statement-evolution-chart ASTRAZENECA-PLC

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	24,384	26,617	37,417	44,351	45,811	53,290	57,208	60,616
Change	-	9.16%	40.58%	18.53%	3.29%	16.32%	7.35%	5.96%
EBITDA ¹	6,686	8,311	7,586	9,237	13,580	17,046	20,106	22,085
Change	-	24.3%	-8.72%	21.76%	47.02%	25.52%	17.95%	9.84%
EBIT ¹	6,436	7,340	9,928	13,350	14,534	17,072	19,249	21,130
Change	-	14.05%	35.26%	34.47%	8.87%	17.46%	12.75%	9.77%
Interest Paid ¹	-765	-782	-862	-1,251	-1,282	-1,186	-965.2	-947
Earnings before Tax (EBT) ¹	1,548	3,916	-265	2,501	6,899	10,661	13,210	15,162
Change	-	152.97%	-	-	175.85%	54.53%	23.91%	14.77%
Net income ¹	1,335	3,196	112	3,288	5,961	8,363	10,175	11,680
Change	-	139.4%	-96.5%	2,835.71%	81.3%	40.3%	21.66%	14.79%
Announcement Date	2/14/20	2/11/21	2/10/22	2/9/23	2/8/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: Diciembre	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	6,664	6,354	6,275	6,578	7,410	7,320	8,220	9,866	12,011	11,390	10,771	10,982	11,207	10,879	11,416	11,492	12,024	12,679	12,938	13,565	14,135	13,590	13,795	14,185	14,900
Change	-	-4.65%	-1.24%	4.83%	12.65%	-1.21%	12.3%	20.02%	21.74%	-5.17%	-5.43%	1.96%	2.05%	-2.93%	4.94%	0.67%	4.63%	5.45%	2.04%	4.85%	4.2%	-3.86%	1.51%	2.83%	5.04%
EBITDA ¹	2,220	2,061	1,994	1,972	2,284	2,692	1,880	1,114	1,900	2,187	1,896	2,579	2,574	-	3,732	-	-	-	4,025	3,923	5,608	-	-	-	-
Change	-	-7.16%	-3.25%	-1.1%	15.82%	17.86%	-30.16%	-40.74%	70.56%	15.11%	-13.31%	36.02%	-0.19%	-100%	-	-100%	-	-	-	-2.53%	42.95%	-100%	-	-	-
EBIT ¹	1,545	1,854	1,792	1,795	1,899	2,524	1,805	2,281	3,318	3,961	3,365	3,413	2,610	3,946	4,291	3,545	2,752	4,310	4,101	4,318	4,457	-	-	-	-
Change	-	20%	-3.34%	0.17%	5.79%	32.91%	-28.49%	26.37%	45.46%	19.38%	-15.05%	1.43%	-23.53%	51.19%	8.74%	-17.39%	-22.37%	56.61%	-4.85%	5.29%	3.21%	-100%	-	-	-
Charge d'intérêts	-186	-169	-307	-317	-205	-187	-319	-320	-234	-194	-223	-324	-315	-287	-262	-291	-337	-302	-285	-274	-	-	-	-	-
Earnings before Tax (EBT)	240	935	961	853	1,167	1,608	764	-2,001	-636	553	247	922	778	2,262	2,088	1,652	897	2,800	2,397	1,828	-	-	-	-	-
Change	-	289.58%	2.78%	-11.24%	36.81%	37.79%	-52.49%	-	-68.22%	-	-55.33%	273.28%	-15.62%	190.75%	-7.69%	-20.88%	-45.7%	212.15%	-14.39%	-23.74%	-100%	-	-	-	-
Net income ¹	313	780	756	648	1,012	1,561	550	-1,652	-347	386	360	1,640	901	1,803	1,818	1,378	959	2,179	1,927	1,429	3,833	-	-	-	-
Change	-	149.2%	-3.08%	-14.29%	56.17%	54.25%	-64.77%	-	-79%	-	-6.74%	355.56%	-45.06%	100.11%	0.83%	-24.2%	-30.41%	127.22%	-11.56%	-25.84%	168.26%	-100%	-	-	-
Announcement Date	2/14/20	4/29/20	7/30/20	11/5/20	2/11/21	4/30/21	7/29/21	11/12/21	2/10/22	4/29/22	7/29/22	11/10/22	2/9/23	4/27/23	7/28/23	11/9/23	2/8/24	4/25/24	7/25/24	11/12/24	-	-	-	-	-

¹USD in Million

Estimates

Fiscal Period: Diciembre	2024 S1
Net sales ¹	25,617
Change	-
EBITDA	-
Change	-
EBIT ¹	8,411
Change	-
Charge d'intérêts	-
Earnings before Tax (EBT)	-
Change	-
Net income	-
Change	-
Announcement Date	7/25/24

¹USD in Million

Estimates

Forecast Balance Sheet: AstraZeneca PLC

balance-sheet-analysis-chart ASTRAZENECA-PLC

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	12,009	11,867	24,383	22,923	22,510	22,612	16,952	9,193
Change	-	-1.18%	105.47%	-5.99%	-1.8%	0.45%	-25.03%	-45.77%
Announcement Date	2/14/20	2/11/21	2/10/22	2/9/23	2/8/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: AstraZeneca PLC

Fiscal Period: Diciembre	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	979	961	1,091	1,091	1,361	2,016	2,048	2,102
Change	-	-1.84%	13.53%	0%	24.75%	48.09%	1.59%	2.64%
Free Cash Flow (FCF) ¹	1,990	3,838	4,872	8,717	8,984	7,084	11,698	13,756
Change	-	92.86%	26.94%	78.92%	3.06%	-21.14%	65.13%	17.59%
Announcement Date	2/14/20	2/11/21	2/10/22	2/9/23	2/8/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: AstraZeneca PLC

Fiscal Period: Diciembre	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	27.42%	31.22%	20.27%	20.83%	29.64%	31.99%	35.15%	36.43%
EBIT Margin (%)	26.39%	27.58%	26.53%	30.1%	31.73%	32.04%	33.65%	34.86%
EBT Margin (%)	6.35%	14.71%	-0.71%	5.64%	15.06%	20.01%	23.09%	25.01%
Net margin (%)	5.47%	12.01%	0.3%	7.41%	13.01%	15.69%	17.79%	19.27%
FCF margin (%)	8.16%	14.42%	13.02%	19.65%	19.61%	13.29%	20.45%	22.69%
FCF / Net Income (%)	149.06%	120.09%	4,350%	265.12%	150.71%	84.71%	114.97%	117.77%
Profitability
ROA	2.19%	4.99%	8.77%	3.26%	11.48%	9.43%	11%	12.05%
ROE	35.58%	36.72%	27.51%	27.23%	29.77%	30.36%	31.38%	31.27%
Financial Health
Leverage (Debt/EBITDA)	1.8x	1.43x	3.21x	2.48x	1.66x	1.33x	0.84x	0.42x
Debt / Free cash flow	6.03x	3.09x	5x	2.63x	2.51x	3.19x	1.45x	0.67x
Capital Intensity
CAPEX / Current Assets (%)	4.01%	3.61%	2.92%	2.46%	2.97%	3.78%	3.58%	3.47%
CAPEX / EBITDA (%)	14.64%	11.56%	14.38%	11.81%	10.02%	11.82%	10.18%	9.52%
CAPEX / FCF (%)	49.2%	25.04%	22.39%	12.52%	15.15%	28.45%	17.5%	15.28%
Items per share
Cash flow per share ¹	2.282	3.655	4.179	6.287	6.623	8.294	10.29	11.57
Change	-	60.17%	14.33%	50.46%	5.34%	25.23%	24.12%	12.39%
Dividend per Share ¹	2.8	2.8	2.87	2.9	2.9	3.105	3.275	3.432
Change	-	0%	2.5%	1.05%	0%	7.07%	5.46%	4.8%
Book Value Per Share ¹	10.09	11.91	27.69	23.93	25.06	26.78	29.92	34.11
Change	-	18.04%	132.51%	-13.6%	4.74%	6.87%	11.72%	14.01%
EPS ¹	1.03	2.44	0.08	2.11	3.81	5.43	6.597	7.589
Change	-	136.89%	-96.72%	2,537.5%	80.57%	42.53%	21.49%	15.03%
Nbr of stocks (in thousands)	1,311,913	1,312,660	1,549,159	1,549,528	1,549,926	1,550,287	1,550,287	1,550,287
Announcement Date	2/14/20	2/11/21	2/10/22	2/9/23	2/8/24	-	-	-